News and Updates
QART MEDICAL – SPIE 2023 Startup Challenge
QART Medical is proud to announce its recent win at the International Society for Optics and Photonics (SPIE) 13th annual Startup Challenge. Held annually at SPIE’s flagship event, Photonics West, the Startup Challenge is designed to showcase innovative companies and technologies that use photonics to address unmet needs in healthcare and deep-tech.
Read moreQART MEDICAL has Completed Enrollment in its Multi-Center Clinical Study
QART Medical, Raanana, Israel: QART is excited to announce the completion of patient enrollment in the Feasibility, Usability & Performance multi-center clinical study of the Q300™ system. QART anticipates having final results from this study during Q1 2023. Interim results indicate a favorable agreement between the Q300™ and “gold standard” measurements, good usability, and the great importance of using the Q300™ system, in selecting WHO2021-compliant sperm cells.
Read moreQART MEDICAL – FDA Registration
QART Medical is excited to announce a major milestone for our company: We have registered our flagship product, the Q300™ with the United States Food and Drug Administration (FDA). The Q300™ system empowers embryologists to make objective, quantitative, recorded, and highly-informed decisions about the sperm cells that they intend to select for injection into oocytes during the most prevalent IVF procedure, ICSI (intra cytoplasmic sperm injection).
Read moreQART Medical – Presentation at the JSRM 2022 Conference
QART Medical presented at the 67th Annual Meeting of the Japan Society for Reproductive Medicine, on November 3-4th, 2022 (see: http://www.jsrm.or.jp/en/meetings_sch.html).
The conference took place in the Pacifico Yokohama Conference Center, Tokyo, Japan. The QART team showcased the Q300™ system, which empowers embryologists to make objective, quantitative, recorded, and highly-informed decisions about the sperm cells they select for injection into oocytes during IVF. The QART team was joined by our partners at Chartered Investment Managers who provided excellent in-country support. QART’s groundbreaking technology and the Q300™ system, were presented to embryologists, reproductive-medicine research scientists, hospital administrators and medical device distributors.
QART Medical, a Male Fertility Company, Discloses Recent Financing
October 20th, Raanana, Israel – The round was led by Chartered Group, an SEA-based investment management fund and included Hamamatsu Photonics and angel investors.
Read moreQART-Medical receives ISO13485 certificate
QART Medical is a MedTech startup, focusing on male fertility utilizing cutting edge bio-photonics technologies, originating from a decade’s work of Prof. Natan T. Shaked’s group in Tel-Aviv University.
Read moreQART Medical Ltd. has received ethical committee approvals
QART Medical Ltd. has received ethical committee approvals to commence clinical studies in medical centres in Israel. QART Medical is an MedTech start-up, addressing the huge unmet need of male infertility.
Read moreQart Medical Ltd. receives Seal of Excellence from EU Horizon 2020
Read moreQART Medical Ltd. has won the 3rd (monetary) prize in the 2020 from QCII
QART Medical Ltd. has won the 3rd (monetary) prize in the 2020 Qingdao High-tech Zone Lanebest International Innovation and Entrepreneurship Competition.
Read more